Navigation Links
Genaera Discontinues Lomucin in Cystic Fibrosis Studies

Genaera Corporation announced that, in conjunction with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), both parties have agreed for reasons of futility to discontinue the Phase 2 study of LOMUCIN(TM) for the treatment of cystic fibrosis (CF). Genaera also announced that the Phase 2 study of squalamine in prostate cancer, which is an investigator-initiated study funded by the Department of Defense, will also be discontinued.

"Earlier this year we redefined our business strategy and committed to focus our efforts on our two core assets, trodusquemine (MSI-1436) for obesity and the anti-IL-9 (MEDI-528) program licensed to MedImmune, Inc. for the treatment of asthma, and continue efforts to monetize our non-core assets. Our announcement today is consistent with that strategy and serves as validation that we are executing upon it," stated Jack Armstrong, President and CEO of Genaera.

Mr. Armstrong continued, "We continue to be very encouraged by the progress of the MEDI-528 Phase 2 program in asthma. This is an asset that is below the radar screen of many, and we believe has greater present and future value than is currently recognized by the market. Separately, our trodusquemine Phase 1 study in obesity is progressing nicely through the initial cohorts in Study 101 to test safety and PK. We believe this program, in addition to anti-IL-9, will generate significant additional interest in the Company in the near future as additional data becomes available."

As a result of the joint decision to terminate the LOMUCIN study, the CFFT has agreed to final financial details of the award agreement to support the evaluation of LOMUCIN in subjects with CF. Genaera will receive a final milestone payment in the amount of $100,000 and will not be required to refund any portion of the award previously received from the CFFT. As a result of termination, the Company will recognize revenue of $2,102,000 of which $2,002,000 was previously r ecorded as a long-term liability.

Termination of the LOMUCIN study was a result of a recommendation by the Company to the study's Data Monitoring Committee (DMC) to close the ongoing study for futility. The DMC identified no safety concerns in their review.

"Genaera and the Data Monitoring Committee planned a joint evaluation of the midpoint data from the LOMUCIN study to determine if the enrollment of the final subjects in the study would allow us to better understand the impact of the drug on respiratory function in cystic fibrosis patients. The committee determined that there is no additional benefit to further enrollment, so we found it reasonable to conclude the study, evaluate the impact of the drug, and move forward focused on our core programs," stated Michael J. Gast, M.D., Ph.D., Executive Vice President of Clinical Research and Development at Genaera. "We believe that the data from this LOMUCIN study continues to validate the drug's target, hCLCA1, as a potential target for future research in respiratory and other diseases and we maintain a strong intellectual property position and library of over 15,000 compounds for this target."

The Phase 2 study of squalamine in prostate cancer, another of Genaera's non-core assets, was also discontinued. There had been no recent enrollment in this trial, and delays in restarting the study at a new investigative site made the decision to end the study appropriate.


'"/>




Related medicine news :

1. Gene Therapy For Cystic Fibrosis
2. Surprising Cystic Fibrosis Finding That Could Be A Helpful Treatment Option
3. The Use Of Colistin To Treat Cystic Fibrosis Questioned
4. Cystic fibrosis patients may require a new treatment for bacterial infection
5. Treatment for Cystic Fibrosis in the future
6. New Therapy Discovered By Scientists For Cystic Fibrosis
7. Inhaling Concentrated Saline Could Benefit Cystic Fibrosis Patients
8. New Multi-functional Sensing Tool To Investigate Cystic Fibrosis
9. Protein May Offer New Hope For Treatment Of Cystic Fibrosis
10. Cellular System Causing Destruction Of Faulty Proteins In Cystic Fibrosis Identified
11. Gene Therapy To The Aid Of Cystic Fibrosis.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... ... 2017 , ... Sideline Products participated in the World Horse Expo held in ... and his production crew. Tom Seay’s program “Best of America by Horseback” is ... Sidekicks will be featured on April 6, 2017. After the broadcast, the clip will ...
(Date:2/22/2017)... ... February 22, 2017 , ... The first-ever National ... organizations, advocates, and individuals join together to increase recognition about the risks of ... lives. , “Today we mark a nationwide movement to raise awareness about a ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... issues related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as ... one of a small number of neurosurgeons in Michigan performing minimally invasive back ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... company, launched a new media platform connecting healthcare technology professionals and other key ... followed by a quarterly publication starting on March 1, announced Michael J. Hennessy, ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the Athens Home Show ... Georgia. , A shift from Super-Sod’s simple Athens Home Show booth of 2016, this ... grass seed plant manager Chris Roquemore constructed furniture from recycled pallet wood at the ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)...  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... fourth quarter and full year 2016 financial results on Thursday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at 4:30 ... be obtained as follows: Thursday, March 2 ...
(Date:2/22/2017)... N.J. , Feb. 22, 2017  Andre, DiMino, ... technology-based developer and manufacturer of innovative technologies and products, ... results reported on February 21, 2017 in the Company,s ... . ADMT CEO Andre, DiMino stated "During ... our business plan by devoting a larger portion of ...
(Date:2/22/2017)... -- Ultra Clean Holdings, Inc. (Nasdaq: UCTT), a leading ... for the semiconductor capital equipment, flat panel, medical, ... results for the fourth quarter and fiscal year ... a year of extraordinary growth for UCT. Total ... together with continued focus on operational excellence resulted ...
Breaking Medicine Technology: